Navigation Links
New Research Shows Effectiveness of Stereotactic Body Radiotherapy for Spinal Tumors
Date:8/17/2009

MIAMI, Aug. 17 /PRNewswire/ -- Stereotactic body radiotherapy (SBRT) is a highly effective alternative treatment for some cancer patients with spinal metastases, reported in new research from The University of Texas in Houston, according to James G. Schwade, M.D. Executive Director of the CyberKnife Centers of Miami and Palm Beach.

(www.cyberknifemiami.com)

"This data confirms the established method of cancer treatment used on spinal tumors and other hard to reach areas of the body, due to the precisely targeted radiation dose and non-invasive nature of radiosurgery," said Dr. Schwade.

The study was presented at the American Association of Neurological Surgeons annual meeting in San Diego.

"SBRT offers patients a minimally invasive treatment option they previously did not have," said Dr. Eric L. Chang. "We are also able to offer patients a degree of pain control and to decrease their pain medications, minimizing the side effects from those medications."

In the study, researchers evaluated 121 cancer patients with metastases to the spine who underwent intensity-modulated, near simultaneous, CT image-guided SBRT, said Dr. Chang.

Researchers used a stereotactic body frame system consisting of a whole-body vacuum cushion and plastic fixation sheet used to immobilize patients for the treatment period, which lasts approximately one hour.

The team performed MR imaging of the spine within 30 days of patient enrollment, every three months for the first year and every six months after that. Patients also evaluated their own pain and other discomfort using instruments including the validated Brief Pain Inventory and the M.D. Anderson Symptom Inventory.

The CyberKnife Centers of Miami and Palm Beach serve the Palm Beach, Broward and Miami Dade County areas with outpatient facilities treating cancer patients with stereotactic radiosurgery utilizing the CyberKnife. For more information please visit http://www.morsecyberknife.com or http://www.ca123.com.


'/>"/>
SOURCE CyberKnife Centers of Miami and Palm Beach
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):